Alzheimer’s is a leading cause for disability and dependency in later life. We’re working towards changing this.

Alzheimer’s Affects Everyone

1 out of 9 people over the age of 65 suffer from Alzheimer’s disease. But really, it affects everyone. A progressive disease, initial symptoms of Alzheimer’s include memory loss. During late-stage Alzheimer’s, individuals lose the ability to care for themselves and can no longer respond to their environment. While frustrating for Alzheimer patients, friends and family members are forced to watch as their loved one transforms into a silhouette of their former, healthy selves.

A characteristic of Alzheimer’s disease is the accumulation of beta-amyloid plaques in the brain. Since the retina is an extension of the brain, this provides clinicians and researchers with critical access for identifying beta-amyloid plaques, known as a key biomarker of Alzheimer’s. In turn, leading to the early detection of this horrible disease.


Clinical Trials – Changing the Future of Alzheimer’s

We are transforming understanding of age-related memory loss by bringing cutting edge imagery and Artificial Intelligence at your local eye clinic.

With research we can make memory loss a souvenir

over 5 million
americans suffers from
Alzheimer’s disease

Our experts

Optina Diagnostics is made up of a driven and dynamic team of experts in the areas of business development, research, and finance.

David Lapointe, M. Sc.

President and CEO

Chantal Miklosi


Jean-Philippe Sylvestre, ing., M.Sc., Ph.D.


Claudia Chevrefils, ing., Ph.D.


Marie-Claude Marchand Bsc. MBA

Vice-President Business Development

Marie-Andrée Tremblay, ing.

Scientific Team

George Mallin, MSME, MBA

Product Manager

Gabriel Dignard

Scientist in image analysis

Sébastien Blais Ouellette, Ph.D.

Board of Directors

Jean Daniel Arbour

Board of Directors